Printer Friendly

GiiResearch.com: Global Musculoskeletal Disorders Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise.

Hartford, CT, January 21, 2012 --(PR.com)-- Global Information Inc. (GII) is pleased to announce a new market research report “Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014” by GBI Research.

Global Musculoskeletal Disorders market was approximately valued $33.4 billion, representing a compound annual growth rate (CAGR) of 5.7% between 2002 and 2010. By 2017, the global market is estimated to reach $54.8 billion, indicating a CAGR of 7.3% between 2010 and 2017.

The global musculoskeletal disorders therapeutics market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). While the current market pipeline has a prospect for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the market's generic share continues to rise.

About the report

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy. The report also provides the share of generics in the global musculoskeletal disorders as well as in each indication market. It also provides the treatment flow algorithm for each of the five indications. The report examines the global musculoskeletal disorders treatment usage patterns. In addition, our research details the geographical distribution of musculoskeletal disorders markets across the US, the top five countries of Europe, and Japan.The report also includes insight into the musculoskeletal disorders R&D product pipeline and explores the competitive landscape, including major players in the musculoskeletal disorders therapeutics market. Finally, the report includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the musculoskeletal disorders therapeutics market in recent years.

For further details on this report, visit: http://www.giiresearch.com/report/gbi227860-musculoskeletal-disorders-therapeutics-market-2017.html

Browse Bone Disease Treatment market research reports: http://www.giiresearch.com/topics/PH06_en.shtml

About Global Information Inc.

Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

###

Contact Information:

Global Information Inc.

Yuko Ueki

860-674-8796

Contact via Email

http://www.GiiResearch.com
COPYRIGHT 2012 PR.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR.com (Press Releases)
Article Type:Industry overview
Date:Jan 21, 2012
Words:458
Previous Article:Supply of Rare and Precious Metals Will Remain Tight Despite Growing Demand from Manufacturers and Investors.
Next Article:GiiResearch.com: Antifungals Market to Reach $10.8 Billion by 2017.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters